Skip to content

Study · Randomized controlled trial · n = 32 · 2017

1 result

Acute Testosterone Deficiency Alters Adipose Tissue Fatty Acid Storage.

Santosa S, Bush NC, Jensen MD

The Journal of clinical endocrinology and metabolism1 Aug 2017Cited by 31 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialMechanism

    In male volunteers, Lupron-induced testosterone deficiency increased femoral adipose tissue meal fatty acid storage rate, fasting and fed LPL activity, and ACS activity versus the no-treatment control and Lupron plus testosterone groups.

    In plain wordsLupron raised thigh fat fatty acid storage and related enzyme activity versus untreated men and men given Lupron plus testosterone.

    Peptide
    Leuprolide
    Outcome
    IncreaseFemoral adipose fatty acid storage mechanisms
    Study

    n = 32

    Comparator
    No-treatment control and Lupron plus testosterone replacement (L+T)
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    7.5 mg · injection · 49 daysAs given in this study (human).

    Source sentences

    Summary
    Compared with control and L+T groups, acute testosterone deficiency resulted in greater femoral adipose tissue meal FA storage rates, fasting and fed LPL activity, and ACS activity.
    3 context sentences
    Summary · context
    This was a prospective, randomized trial.
    Summary · context
    Thirty-two male volunteers ages 18 to 50 participated in these studies.
    Summary · context
    Volunteers were randomized to receive (1) no treatment (control), (2) injections (7.5 mg) of Lupron®, or (3) Lupron and testosterone (L+T) replacement for 49 days, resulting in 4 weeks of sex steroid suppression in the Lupron group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.